A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

BACKGROUND: Staphylococcus aureus bacteremia is a common infection associated with significant morbidity and mortality. Telavancin is a bactericidal lipoglycopeptide active against Gram-positive pathogens, including methicillin-resistant S. aureus (MRSA). We conducted a randomized, double-blind, Pha...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	Stryjewski, Martin E, Lentnek, Arnold, O’Riordan, William, Pullman, John, Tambyah, Paul Anantharajah, Miró, Jose M, Fowler Jr, Vance G, Barriere, Steven L, Kitt, Michael M, Corey, G Ralph
Format:	Artigo
Sprog:	Inglês
Udgivet:	BioMed Central 2014
Fag:	Research Article
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4048626/ https://ncbi.nlm.nih.gov/pubmed/24884578 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2334-14-289
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

Lignende værker